Kerry Rogers

30PUBLICATIONS
203CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)HaematologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (30)

|Jul 14, 2026
Safety and clinical outcomes of a first-in-human trial of point-of-care manufactured trispecific CAR T cells targeting CD19, CD20, and CD22.

|Apr 22, 2026
Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib.

|Apr 14, 2026
Updated consensus guidelines for the diagnosis and management of patients with HCL and HCL variant.

Clive S Zent, Enrico Tiacci, Robert J Kreitman

|Nov 06, 2025
Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study.

Kerry A Rogers, Pearlly Yan, Ian W Flinn

|Nov 05, 2025
PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor-Resistant Chronic Lymphocytic Leukemia.

Britten K Gordon, Elizabeth M Muhowski, Jyotsana Singh

|Apr 22, 2025
A comparison of healthcare resource utilization and costs between patients with chronic lymphocytic leukemia treated with first-line ibrutinib or acalabrutinib using two large US real-world databases.

Kerry A Rogers, Benyam Muluneh, Zaina P Qureshi

Pageof 5

Frequent Collaborators

8 joint publications

Jennifer A Woyach

6 joint publications

Seema Bhat

5 joint publications

James S Blachly

5 joint publications

Deborah M Stephens